Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifluridine/Tipiracil in pretreated metastatic colorectal cancer (PRECONNECT)
NCT03306394Phase 3Completed
- Sponsor
- Servier
- Start
- Oct 2016
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, open-label, single-arm trial of trifluridine + tipiracil in metastatic colorectal cancer (mCRC), sponsored by Servier. Primary endpoints: Incidence of Adverse Events, Abnormalities in laboratory assessment and 2 more. Started Oct 2016; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03306394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03306394.